Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple‐negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this a...

Descripción completa

Detalles Bibliográficos
Autores principales: Miglietta, Federica, Griguolo, Gaia, Guarneri, Valentina, Dieci, Maria Vittoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853089/
https://www.ncbi.nlm.nih.gov/pubmed/31444294
http://dx.doi.org/10.1634/theoncologist.2019-0197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853089/
https://www.ncbi.nlm.nih.gov/pubmed/31444294
http://dx.doi.org/10.1634/theoncologist.2019-0197

Ejemplares similares